Literature DB >> 6297399

Different behaviors of benznidazole as free radical generator with mammalian and Trypanosoma cruzi microsomal preparations.

S N Moreno, R Docampo, R P Mason, W Leon, A O Stoppani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6297399     DOI： 10.1016/0003-9861(82)90383-6

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN： 0003-9861            Impact factor:   4.013


× No keyword cloud information.
  14 in total

1.  Benznidazole, a drug employed in the treatment of Chagas' disease, down-regulates the synthesis of nitrite and cytokines by murine stimulated macrophages.

Authors:  S Revelli; C Le Page; E Piaggio; J Wietzerbin; O Bottasso
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

2.  Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation.

Authors:  Belinda S Hall; Shane R Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2011-10-28       Impact factor: 5.191

3.  Identification of N-benzylacetamide as a major component of human plasmatic metabolic profiling of benznidazole.

Authors:  María Elena Marson; Jaime Altcheh; Guillermo Moscatelli; Samanta Moroni; Facundo García-Bournissen; Guido Enrique Mastrantonio
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-04-08       Impact factor: 2.441

4.  Putative Role of the Aldo-Keto Reductase from Trypanosoma cruzi in Benznidazole Metabolism.

Authors:  Patricia Andrea Garavaglia; Marc Laverrière; Joaquín J B Cannata; Gabriela Andrea García
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

5.  Interaction of benznidazole reactive metabolites with nuclear and kinetoplastic DNA, proteins and lipids from Trypanosoma cruzi.

Authors:  E G Díaz de Toranzo; J A Castro; B M Franke de Cazzulo; J J Cazzulo
Journal:  Experientia       Date:  1988-10-15

6.  Concomitant Benznidazole and Suramin Chemotherapy in Mice Infected with a Virulent Strain of Trypanosoma cruzi.

Authors:  Eliziária C Santos; Rômulo D Novaes; Marli C Cupertino; Daniel S S Bastos; Raphael C Klein; Eduardo A M Silva; Juliana L R Fietto; André Talvani; Maria T Bahia; Leandro L Oliveira
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

7.  Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox.

Authors:  Mario Faúndez; Rodrigo López-Muñoz; Gloria Torres; Antonio Morello; Jorge Ferreira; Ulrike Kemmerling; Myriam Orellana; Juan D Maya
Journal:  Antimicrob Agents Chemother       Date:  2008-03-10       Impact factor: 5.191

Review 8.  Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina.

Authors:  Facundo Garcia-Bournissen; Jaime Altcheh; Norberto Giglio; Guido Mastrantonio; Carlos Omar Della Védova; Gideon Koren
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

9.  Effect of tingenone, a quinonoid triterpene, on growth and macromolecule biosynthesis in Trypanosoma cruzi.

Authors:  S G Goijman; J F Turrens; G B Marini-Bettolo; A O Stoppani
Journal:  Experientia       Date:  1985-05-15

10.  Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population.

Authors:  Ana Maria Mejia; Belinda S Hall; Martin C Taylor; Andrés Gómez-Palacio; Shane R Wilkinson; Omar Triana-Chávez; John M Kelly
Journal:  J Infect Dis       Date:  2012-05-02       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.